Search Site

Neuropathy Research

In collaboration with neurologists, endocrinologists, other physicians, and basic scientists, the Columbia Neuropathy Research Center is committed to basic and human research designed to improve our understanding and effective treatment of peripheral and autonomic neuropathies of all types.

The CNRC is funded exclusively by donor support and research grants.


New Study:

A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of VM202 in Subjects with Painful Diabetic Peripheral Neuropathy

This is a Phase III study of the experimental drug VM202. VM202 is a DNA plasmid encoding human hepatocyte growth factor (HGF).  HGF is known to be a potent angiogenic and potentially neurogenic agent.  In phase I and II studies, a single treatment of intramuscular injections of VM202 into the calves of patients with painful DPN resulted in significant reductions in pain at 3 and 6 months, as well as improvements in monofilament testing.  

In this study, patients will receive 2 treatments of either VM202 or placebo at baseline and 2 months; randomization will be 2:1 to VM202 or placebo.  The study will be 9 months long and include 477 patients.
Click here for additional information

 

New Study:

GRIPPER: Intravenous Immunoglobulin (IVIg) Treatment-Related Fluctuations in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Patients Using Daily Grip Strength Measurements

This is a prospective observational study of 30 adult CIDP patients who receive home IVIg infusion services from AxelaCare Health Solutions, LLC. The decision to treat with IVIg will be entirely at the discretion of the patient's treating physician.
Click here for additional information



For more information and to see if you qualify, please call:
The Columbia Neuropathy Research Center
The Neurological Institute
710 West 168th Street, 2nd floor
New York, NY 10032
Tel. 212-305-6035